Benitec Biopharma Limited
BNTCW
BNTCW was delisted on the 14th of April, 2020.
3 hedge funds and large institutions have $56K invested in Benitec Biopharma Limited in 2017 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
33% more capital invested
Capital invested by funds: $42K → $56K (+$14K)
0% more funds holding
Funds holding: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$170 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $36K | – | – | – |
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $20K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| – | +$170 | +459 | +119% |
|
BNTCW Hedge Fund Activity: Q4 2017 in Review
3 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma Limited (BNTCW) for Q4 2017, worth a combined $56K — up 33% from $42K a quarter earlier.
Fund positioning in BNTCW was balanced in Q4 2017: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $170.
- 3 institutional investors held Benitec Biopharma Limited (BNTCW) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $56K of Benitec Biopharma Limited stock for Q4 2017, up 33% quarter-over-quarter.
- 0 funds opened new Benitec Biopharma Limited positions in Q4 2017 and 0 closed out.
- The largest Benitec Biopharma Limited buyer in Q4 2017 was UBS Group, an estimated $170 added.
Based on aggregated 13F filings for Q4 2017.